Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy

SIMPLE SUMMARY: We report the final outomes of the addition of ixazomib to the combination of lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma in the routine clinical practice. With prolonged follow-up, the overall response rate was similar in both cohorts, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Minarik, Jiri, Radocha, Jakub, Jungova, Alexandra, Straub, Jan, Jelinek, Tomas, Pika, Tomas, Pour, Ludek, Pavlicek, Petr, Harvanova, Lubica, Pospisilova, Lenka, Krhovska, Petra, Novakova, Denisa, Jindra, Pavel, Spicka, Ivan, Plonkova, Hana, Stork, Martin, Bacovsky, Jaroslav, Maisnar, Vladimir, Hajek, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601107/
https://www.ncbi.nlm.nih.gov/pubmed/36291949
http://dx.doi.org/10.3390/cancers14205165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601107/
https://www.ncbi.nlm.nih.gov/pubmed/36291949
http://dx.doi.org/10.3390/cancers14205165

Ejemplares similares